Alexion and Elliott Agree to Collaborate on Identifying a New Board Member
January 02 2018 - 4:05PM
Business Wire
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) said today that its
Board of Directors and Elliott have agreed to work collaboratively
to promptly identify a new member to join the Alexion Board.
Alexion announced in November that it had a search underway to fill
an open Board seat and is seeking candidates who represent a range
of backgrounds, perspectives, skills, and expertise, with an
emphasis on maintaining a diverse Board.
David Brennan, Chairman of Alexion’s Board of Directors, said,
“This agreement is in line with our ongoing efforts to maintain
active and constructive dialogue with all of our shareholders and
to identify a new board member with a proven track record of
building value. We have been actively working to expand and
diversify our Board, and we welcome input from Elliott to identify
a strong director candidate to further strengthen Alexion’s
Board.”
An Elliott spokesperson stated, “Elliott is pleased to reach
agreement with Alexion to identify a new independent director to
join the Company’s Board of Directors. We are encouraged by
actions taken under Ludwig’s leadership to improve financial
performance and re-set Alexion’s strategy. Enhancing the strength
of the Board is another step toward maximizing value creation for
all shareholders.”
About Alexion
Alexion is a global biopharmaceutical company focused on serving
patients and families affected by rare diseases through the
innovation, development and commercialization of life-changing
therapies. Alexion is the global leader in complement inhibition
and has developed and commercializes the first and only approved
complement inhibitor to treat patients with paroxysmal nocturnal
hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS),
and anti-acetylcholine receptor (AchR) antibody-positive
generalized myasthenia gravis (gMG). In addition, Alexion has two
highly innovative enzyme replacement therapies for patients with
life-threatening and ultra-rare metabolic disorders,
hypophosphatasia (HPP) and lysosomal acid lipase deficiency
(LAL-D). As the leader in complement biology for over 20 years,
Alexion focuses its research efforts on novel molecules and targets
in the complement cascade, and its development efforts on the core
therapeutic areas of hematology, nephrology, neurology, and
metabolic disorders. This press release and further information
about Alexion can be found at: www.alexion.com.
[ALXN-G]
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. These forward-looking statements often include words such
as "anticipate," "believe," "expect," "will," or similar
expressions. Forward-looking statements are subject to factors that
may cause Alexion's results and plans to differ from those
expected, including the risks set forth from time to time in
Alexion's filings with the U.S. Securities and Exchange Commission,
including but not limited to the risks discussed in Alexion's
Quarterly Report on Form 10-Q for the period ended September 30,
2017 and in our other filings with the U.S. Securities and Exchange
Commission. Alexion does not intend to update any of these
forward-looking statements to reflect events or circumstances after
the date hereof, except when a duty arises under law.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180102005790/en/
Alexion Pharmaceuticals, Inc.Media:Kim Diamond,
475-230-3775Executive Director, Corporate
CommunicationsorInvestors:Elena Ridloff, CFA, 475-230-3601Vice
President, Investor RelationsorCatherine Hu, 475-230-3599Director,
Investor Relations
Alexion Pharmaceuticals (NASDAQ:ALXN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Alexion Pharmaceuticals (NASDAQ:ALXN)
Historical Stock Chart
From Sep 2023 to Sep 2024